- Company
- COVID-19 response more important for high-risk groups
- by Whang, byung-woo Sep 1, 2025 06:04am
- While COVID-19 has entered an endemic phase and become a resident disease in daily life, it remains a significant threat to high-risk groups like the elderly. In fact, the outbreak of COVID-19, which had slowed down for a while, has been showing an upward trend again. According to the Korea Disease Control and Prevention Agency's Infectious D
- Company
- Capvaxive release imminent in the pneumococcal vaccine mkt
- by Whang, byung-woo Sep 1, 2025 06:03am
- MSD's adult-specific 21-valent protein-conjugated vaccine Capvaxive was granted marketing authorization in Korea by the Ministry of Food and Drug Safety and has emerged as a new competitor in the domestic adult pneumococcal vaccine market. With Prevenar 20 now launched in the market previously contested by Prevenar 13 and Vaxneuvance, Capvaxi
- Company
- CKD says, "New ADC drug enters first clinical trials"
- by Son, Hyung Min Sep 1, 2025 06:03am
- Chong Kun Dang is accelerating its development of a new c-Met-targeted Antibody-Drug Conjugate (ADC). With its newly entered clinical candidate, 'CKD-703,' the company is aiming to secure a best-in-class ADC and is seeking a differentiated strategy in a globally competitive landscape. On August 29, Samsung Medical Center and Aimed Bio co-
- Company
- Ozempic adds indication for patients with diabetes and CKD
- by Son, Hyung Min Aug 29, 2025 06:07am
- Novo Nordisk Korea (General Manager: Kasper Roseeuw Poulsen) announced on the 28th that Ozempic has been approved as a treatment for type 2 diabetes with chronic kidney disease. With this approval, Ozempic is now indicated for: ▲ Use as an adjunct to a two-drug regimen (either alone or in combination with other diabetes medications), in
- Company
- Eylea high-dosage PFS formulation wins nod in Korea
- by Whang, byung-woo Aug 29, 2025 06:04am
- Bayer Korea announced on August 28 that it has received domestic approval for 'Eylea PFS 8mg (aflibercept),' a pre-filled syringe formulation, from the Ministry of Food and Drug Safety (MFDS). The indication for 'Eylea PFS 8mg' has been approved the same as that for the existing Eylea vial formulation. Now, it can be administered more sim
- Company
- "200-day extension for the CMV preemptive therapy Prevymis"
- by Whang, byung-woo Aug 28, 2025 06:10am
- Prevymis (letermovir), a treatment for preventing cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients, is bringing in another paradigm shift as it has entered the '200-day extension criteria.' This drug's influence is expected to grow as the National Health Insurance (NHI) coverage period has been extend
- Company
- Kolon Pharma's active portfolio expansion…new drug·co-dev
- by Son, Hyung Min Aug 28, 2025 06:10am
- Kolon Pharma is increasing its efforts to secure competitiveness in immunology and oncology by combining new drug in-licensing with in-house R&D. Following the introduction of treatments for chronic obstructive pulmonary disease (COPD) and allergies, the company has recently secured a new drug for hypoparathyroidism. Kolon Pharma plans to contin
- Company
- New ADC drug introduced…expands treatment options
- by Son, Hyung Min Aug 28, 2025 06:09am
- New global drugs are awaiting entry into Korea’s antibody-drug conjugate (ADC) market one after another. Following Daiichi Sankyo Korea's application for domestic approval of the ADC anticancer drug ‘Datroway,’ AbbVie Korea is also proceeding with the approval process for its ovarian cancer-targeted ADC ‘Elahere.’ The industry anticipates t
- Company
- Jaypirca’s reimbursement imminent in Korea
- by Eo, Yun-Ho Aug 27, 2025 06:07am
- The BTK inhibitor Jaypirca is likely to be listed for reimbursement soon. According to Dailypharm coverage, the National Health Insurance Service (NHIS) and Lilly Korea recently completed price negotiations for Jaypirca (pirtobrutinib), a treatment for relapsed or refractory mantle cell lymphoma (MCL). As a result, Jaypirca’s reimburs
- Company
- Targeted therapies and antibody drugs enter clinical trials
- by Son, Hyung Min Aug 27, 2025 06:07am
- Korea’s pharmaceutical and biotech industry is accelerating new drug development for pancreatic cancer, a cancer regarded as one of the most intractable cancers. Onconic Therapeutics, Prestige Biopharma, and Aptamer Sciences have each started clinical trials, making their bid into the field. The company plans to test the commercial viability of
